Top 20 life sciences deals list shows 2025 M&A rebound
CURRENT BRIEF VERSION: A new year-end ranking from PharmaShots, produced with DealForma data, spotlights the 20 biggest life sciences deals announced in 2025 and underscores just how sharply dealmaking rebounded across biopharma, medtech, diagnostics, and research tools. PharmaShots’ list spans asset purchases, acquisitions, divestitures, and R&D alliances, including late-year transactions such as Shionogi’s $2.5 billion purchase of Mitsubishi Tanabe Pharma’s business unit tied to RADICAVA, alongside major 2025 deals involving companies such as Pfizer, Merck, Sanofi, Thermo Fisher Scientific, Siemens, and Eli Lilly, whose planned Centessa buyout was valued at about $7.8 billion including contingent value rights. DealForma’s broader 2025 review found global healthcare and life sciences M&A reached 585 transactions worth $269.3 billion including contingents, nearly double 2024 levels, while average upfront cash and equity also increased. Separate PharmaShots reporting also pointed to strong capital formation beyond M&A, with 2025 healthcare IPOs led by Medline Industries’ $7.2 billion raise and Blackstone closing a $6.3 billion life sciences fund at its hard cap. (pharmashots.com)
Why it matters: For veterinary professionals, this isn’t animal health news directly, but it is a useful signal about where capital, platform technologies, and corporate attention are moving across the broader life sciences market. The biggest 2025 deals clustered around derisked, late-stage or commercial assets, AI-enabled discovery, oncology, cardiometabolic disease, neuroscience, diagnostics, and research software, according to DealForma, Deloitte, and other industry analyses. IPO and fund-raising activity told a similar story, with investor appetite for scaled platforms, AI-enabled solutions, precision medicine, and revenue-generating healthcare businesses. That matters because the same financing environment, valuation discipline, and appetite for platform acquisitions can shape diagnostics, therapeutics, and consolidation trends that eventually reach animal health and veterinary-adjacent companies. (deloitte.com)
What to watch: Watch whether 2026 dealmaking stays focused on late-stage assets and platform plays, whether private capital remains active through large specialist funds and take-private proposals such as CVC’s approach to Recordati, and whether that momentum spills over more visibly into animal health, veterinary diagnostics, and pet care services. (deloitte.com)